

**Louisiana Department of Health
Medicaid Pharmaceutical and Therapeutics Committee
628 North Fourth Street
Baton Rouge, LA
Bienville Building, Room #118
May 9, 2025
9:00 AM**

- I. Call to Order Dr. de la Cruz
- II. Parliamentary Business Dr. de la Cruz
 - A. Introduction of Members/Roll Call
 - B. Approval of October 30, 2024 Meeting Minutes
- III. Ethics Haley Williams
- IV. Reports Melwyn Wendt
- V. New Business..... Hind Douiki
 - A. Explanation of TOP\$, Monographs and Cost Sheets
 - B. Therapeutic Class Reviews /Public Testimony Spring 2025
 - 1. Acne Agents, Topical
 - 2. Analgesics, Narcotics Long
 - 3. Analgesics, Narcotics Short
 - 4. Androgenic Agents
 - 5. Angiotensin Modulator Combinations
 - 6. Angiotensin Modulators
 - 7. Antibiotics, GI
 - 8. Antibiotics, Inhaled
 - 9. Antibiotics, Topical
 - 10. Antibiotics, Vaginal
 - 11. Anticoagulants
 - 12. Antiemetic/Antivertigo Agents
 - 13. Antifungals, Oral
 - 14. Antifungals, Topical
 - 15. Antihistamines, First Generation
 - 16. Antimigraine Agents, Other
 - 17. Antimigraine Agents, Triptans
 - 18. Antiparasitics, Topical
 - 19. Antivirals, Oral
 - 20. Antivirals, Topical
 - 21. Beta-Blockers
 - 22. Bladder Relaxant Preparations
 - 23. Bone Resorption Suppression and Related Agents
 - 24. BPH Treatments
 - 25. Calcium Channel Blockers
 - 26. Cephalosporins and Related Antibiotics
 - 27. Cystic Fibrosis, Oral
 - 28. Fluoroquinolones, Oral
 - 29. GI Motility, Chronic
 - 30. Glucagon Agents
 - 31. Growth Factors
 - 32. Growth Hormone

33. H. Pylori Treatment
34. HAE Treatments
35. Hepatitis B Agents
36. Hepatitis C Agents
37. Hepatitis C Agents Treatment Course
38. HIV / AIDS
39. Hypoglycemics, Alpha-Glucosidase Inhibitors
40. Hypoglycemics, Incretin Mimetics/Enhancers
41. Hypoglycemics, Insulin and Related Agents
42. Hypoglycemics, Meglitinides
43. Hypoglycemics, Metformins
44. Hypoglycemics, SGLT2
45. Hypoglycemics, Sulfonylureas
46. Hypoglycemics, TZD
47. Immunosuppressives, Oral
48. Lincosamides/Oxazolidinones/Streptogramins
49. Lipotropics, Other
50. Lipotropics, Statins
51. Macrolides/Ketolides
52. Multiple Sclerosis Agents
53. Multivitamins
54. Nitrofurantoin Derivatives
55. Opiate Dependence Treatments
56. PAH Agents, Oral and Inhaled
57. Pancreatic Enzymes
58. Pediatric Vitamin Preparations
59. Phosphate Binders
60. Pituitary Suppressive Agents, LHRH
61. Platelet Aggregation Inhibitors
62. Prenatal Vitamins
63. Potassium Binders
64. Proton Pump Inhibitors
65. Sinus Node Inhibitors
66. Skeletal Muscle Relaxants
67. Tetracyclines
68. Ulcerative Colitis Agents
69. Uterine Disorder Treatments
70. Vasodilators, Coronary

VI. Single Product Review Spring 2025

1. Antiparkinson's Agents
 - a. Onapgo
 - b. Vyalev Vial
2. Antipsychotics
 - a. Cobenfy
 - b. Cobenfy Starter Pack
 - c. Opipza Film
 - d. Erzofri
3. Cytokine and Cam Antagonists
 - a. Simlandi Kit (Injection) (CF) 100 mg/ml
 - b. Steqeyma Syringe (Subcutaneous), Vial (Injection)
 - c. Pyzchiva Syringe (Subcutaneous), Vial (Injection)
 - d. Selarsdi Syringe (Subcutaneous), Vial (Injection)
 - e. Yesintek Syringe (Subcutaneous), Vial (Injection)

- f. Tremfya Pen (Subcutaneous), Vial (Intravenous)
 - g. Otulfi Syringe (Subcutaneous), Vial (Intravenous)
- 4. Epinephrine, Self-Administered
 - a. Neffy Spray (Nasal)
- 5. Hemophilia Treatment
 - a. Alhemo Pen (Subcutaneous)
 - b. Hymoviz Pen (Subcutaneous)
- 6. Immunomodulators, Atopic Dermatitis
 - a. Ebglyss Syringe (Subcutaneous), Pen (Subcutaneous)
 - b. Nemluvio Pen (Subcutaneous)
- 7. Neuropathic Pain and Select Agents
 - a. Lyrica Solution (Oral)
 - b. Journavx Tablet (Oral)
 - c. Gabarone Tablet (Oral)
- 8. NSAIDS
 - a. Dolobid (Oral)
- 9. Oncology, Oral – Breast
 - a. Itovebi (Oral)
- 10. Oncology, Oral – Hematologic
 - a. Imkeldi Solution (Oral)
 - b. Danziten Tablet (Oral)
- 11. Oncology, Oral – Other
 - a. Romvimza (Oral)
- 12. Oncology, Oral – Skin
 - a. Gomekli Tab Sups (Oral)
- 13. Sickle Cell Anemia Treatments
 - a. Xromi Solution (Oral)

VII. Other Business

VIII. Next Steps

A. Proposed Therapeutic Classes reviewing at Next Meeting

IX. Proposed Next Meeting Dates – Wednesday, November 5, 2025 or Friday, November 7, 2025

X. Public Testimony